<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704271</url>
  </required_header>
  <id_info>
    <org_study_id>1505015940.B</org_study_id>
    <nct_id>NCT04704271</nct_id>
  </id_info>
  <brief_title>Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II</brief_title>
  <acronym>THC-Gender-II</acronym>
  <official_title>Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the acute effects of cannabinoids in women&#xD;
      relative to men and to begin probing the mechanisms that may underlie gender differences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the acute effects of vaporized THC in women relative to men and to begin&#xD;
      probing the mechanisms that may underlie gender differences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS)</measure>
    <time_frame>Changes in &quot;high&quot; assessed over the following timepoints: baseline, +60, +80, +120, +180, +300 minutes after start of oral Dronabinol administration.</time_frame>
    <description>Subjective measure of THC induced &quot;high&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT)</measure>
    <time_frame>Baseline and +80 minutes after start of oral Dronabinol administration.</time_frame>
    <description>Measured as delay recall on the AVLT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cannabis</condition>
  <arm_group>
    <arm_group_label>Delta-9-Tetrahydrocannabinol (THC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg vaporized THC will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo (no active cannabinoids)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled THC</intervention_name>
    <description>4 mg inhaled THC</description>
    <arm_group_label>Delta-9-Tetrahydrocannabinol (THC)</arm_group_label>
    <other_name>Delta-9-Tetrahydrocannabinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo (no active cannabinoids)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one lifetime exposure to cannabis&#xD;
&#xD;
          -  Good physical and mental health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannabis na√Øve individuals&#xD;
&#xD;
          -  Major current or recent stressors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leigh Taylor Flynn, BS</last_name>
    <phone>2039325711</phone>
    <phone_ext>2557</phone_ext>
    <email>leigh.flynn@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Luddy, BS</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4549</phone_ext>
      <email>christina.luddy@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Mohini Ranganathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mohini Ranganathan</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

